These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 17643112)

  • 1. Splicing factor SF3b as a target of the antitumor natural product pladienolide.
    Kotake Y; Sagane K; Owa T; Mimori-Kiyosue Y; Shimizu H; Uesugi M; Ishihama Y; Iwata M; Mizui Y
    Nat Chem Biol; 2007 Sep; 3(9):570-5. PubMed ID: 17643112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
    Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
    FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
    Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
    Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.
    Arai K; Buonamici S; Chan B; Corson L; Endo A; Gerard B; Hao MH; Karr C; Kira K; Lee L; Liu X; Lowe JT; Luo T; Marcaurelle LA; Mizui Y; Nevalainen M; O'Shea MW; Park ES; Perino SA; Prajapati S; Shan M; Smith PG; Tivitmahaisoon P; Wang JY; Warmuth M; Wu KM; Yu L; Zhang H; Zheng GZ; Keaney GF
    Org Lett; 2014 Nov; 16(21):5560-3. PubMed ID: 25376106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
    Folco EG; Coil KE; Reed R
    Genes Dev; 2011 Mar; 25(5):440-4. PubMed ID: 21363962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Discovery of splicing inhibitors and its impact on drug development].
    Kotake Y; Kaida D; Mizui Y; Yoshida M
    Tanpakushitsu Kakusan Koso; 2008 Jan; 53(1):28-35. PubMed ID: 18186300
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
    Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
    Kaida D; Motoyoshi H; Tashiro E; Nojima T; Hagiwara M; Ishigami K; Watanabe H; Kitahara T; Yoshida T; Nakajima H; Tani T; Horinouchi S; Yoshida M
    Nat Chem Biol; 2007 Sep; 3(9):576-83. PubMed ID: 17643111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
    Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
    Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservation of structure and subunit interactions in yeast homologues of splicing factor 3b (SF3b) subunits.
    Igel H; Wells S; Perriman R; Ares M
    RNA; 1998 Jan; 4(1):1-10. PubMed ID: 9436903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High antitumor activity of pladienolide B and its derivative in gastric cancer.
    Sato M; Muguruma N; Nakagawa T; Okamoto K; Kimura T; Kitamura S; Yano H; Sannomiya K; Goji T; Miyamoto H; Okahisa T; Mikasa H; Wada S; Iwata M; Takayama T
    Cancer Sci; 2014 Jan; 105(1):110-6. PubMed ID: 24635824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
    Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
    Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product.
    Hasegawa M; Miura T; Kuzuya K; Inoue A; Won Ki S; Horinouchi S; Yoshida T; Kunoh T; Koseki K; Mino K; Sasaki R; Yoshida M; Mizukami T
    ACS Chem Biol; 2011 Mar; 6(3):229-33. PubMed ID: 21138297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B.
    Aouida M; Eid A; Mahfouz MM
    Biochim Open; 2016 Dec; 3():72-75. PubMed ID: 29450134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor.
    Ghosh AK; Anderson DD
    Org Lett; 2012 Sep; 14(18):4730-3. PubMed ID: 22954141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo.
    Martinez E; Palhan VB; Tjernberg A; Lymar ES; Gamper AM; Kundu TK; Chait BT; Roeder RG
    Mol Cell Biol; 2001 Oct; 21(20):6782-95. PubMed ID: 11564863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
    Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
    Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.